Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024)

Abstract Background Ganirelix, a third-generation GnRH antagonist, is widely used in assisted reproductive technology (ART) for rapid pituitary suppression to prevent premature luteinizing hormone (LH) surges. Despite its extensive clinical use, real-world evidence on its safety in large populations...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yang Yang, Zhiwei Cui, Xiaoshan Feng, Fan Zou, Xiaoling Wu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-04-01
Edice:	BMC Pharmacology and Toxicology
Témata:	Ganirelix Adverse drug events Pharmacovigilance Real-world evidence FAERS JADER
On-line přístup:	https://doi.org/10.1186/s40360-025-00920-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!